WASHINGTON - Disclaimer: What you are about to read are the mere opinions of three biotech executives speaking Tuesday on Sarbanes-Oxley legislation at the Biotechnology Industry Organization's annual convention here.

To survive in tough economic times, a biotech company often needs two things: cash and the ability to reach money and markets overseas.

Walk into any funding firm and you will see mountains of papers summarizing this company's dream and that company's vision. (BioWorld Financial Watch)

More than 300 investors held tight to their money clips and browsed the Palace Hotel in San Francisco last week, shopping for a share in biotechnology's best and brightest companies. (Bioworld Financial Watch)

Despite the tough public financing environment, venture capitalists are more than willing to dole out the dollars to support good ideas, good science and good management. (BioWorld Financial Watch)

Every start-up biotech company dreams about breakthrough product approvals, positive cash flows and becoming global. (BioWorld Financial Watch)